论文部分内容阅读
目的观察二甲双胍联合达英-35治疗多囊卵巢综合征(PCOS)并胰岛素抵抗患者临床效果。方法选取40例多囊卵巢综合征(PCOS)并胰岛素抵抗患者,随即分为2组,分别使用达英-35、二甲双胍联合达英-35治疗6个月,分析比较其治疗前后临床症状及内分泌生化指标的变化。结果两组患者治疗后与治疗前比较,在体重指数(BMI)、腰围与臀围比(WHR)、卵泡刺激素(FSH)方面无明显差异;达英-35组治疗后睾酮(T)、黄体生成素(LH)、空腹血糖/空腹胰岛素(GIR)明显降低及性激素结合蛋白(SHBG)显著升高(P<0.05),三酰甘油(TG)、血清胰岛素样生长因子-1(IGF-1)、C反应蛋白(CRP)无明显变化;联合用药组治疗后T、LH、空腹血糖(FBG)、空腹胰岛素(FINS)、IGF-1、TG、CRP均显著降低,GIR、SHBG水平显著升高(P<0.05)。结论二甲双胍联合达英-35治疗多囊卵巢综合征,能有效控制高雄激素血症,明显改善临床症状,提高胰岛素敏感性。
Objective To observe the clinical effects of metformin combined with daun-35 in the treatment of patients with polycystic ovary syndrome (PCOS) and insulin resistance. Methods Forty patients with PCOS and insulin resistance were enrolled in this study. They were randomly divided into two groups. The patients were treated with up to -35 and metformin plus up to -35 for 6 months. The clinical symptoms and endocrine Biochemical changes. Results There was no significant difference in body mass index (BMI), waist circumference to hip ratio (WHR) and follicle stimulating hormone (FSH) between the two groups after treatment. Before treatment, testosterone (T) LH, fasting insulin (GIR), and SHBG were significantly increased (P <0.05) 1, C-reactive protein (CRP) had no significant change. The levels of T, LH, fasting blood glucose (FBG), fasting insulin (FINS), IGF-1, TG and CRP in the combination group were significantly decreased Increased (P <0.05). Conclusion Metformin combined with da-Ying-35 treatment of polycystic ovary syndrome, can effectively control hyperandrogenism, significantly improve clinical symptoms and improve insulin sensitivity.